FNDC5 inhibits malignant growth of human cervical cancer cells via restraining PI3K/AKT pathway
- 1 April 2024
- journal article
- research article
- Published by Wiley in Journal of Cellular Physiology
- Vol. 239 (6)
Abstract
Cervical cancer (CxCa) is the fourth most frequent cancer in women. This study aimed to determine the role and underlying mechanism of fibronectin type III domain‐containing protein 5 (FNDC5) in inhibiting CxCa growth. Experiments were performed in human CxCa tissues, human CxCa cell lines (HeLa and SiHa), and xenograft mouse model established by subcutaneous injection of SiHa cells in nude mice. Bioinformatics analysis showed that CxCa patients with high FNDC5 levels have a longer overall survival period. FNDC5 expression was increased in human CxCa tissues, HeLa and SiHa cells. FNDC5 overexpression or FNDC5 protein not only inhibited proliferation, but also restrained invasion and migration of HeLa and SiHa cells. The effects of FNDC5 were prevented by inhibiting integrin with cilengitide, activating PI3K with recilisib or activating Akt with SC79. FNDC5 inhibited the phosphorylation of PI3K and Akt, which was attenuated by recilisib. PI3K inhibitor LY294002 showed similar effects to FNDC5 in HeLa and SiHa cells. Intravenous injection of FNDC5 (20 μg/day) for 14 days inhibited the tumor growth, and reduced the proliferation marker Ki67 expression and the Akt phosphorylation in the CxCa xenograft mouse model. These results indicate that FNDC5 inhibits the malignant phenotype of CxCa cells through restraining PI3K/Akt signaling. Upregulation of FNDC5 may play a beneficial role in retarding the tumor growth of CxCa.Keywords
Funding Information
- National Natural Science Foundation of China (31871148, 32071106)
This publication has 40 references indexed in Scilit:
- Evaluation of Long Non-coding RNA (LncRNA) in the Pathogenesis of Chemotherapy Resistance in Cervical Cancer: Diagnostic and Prognostic ApproachMolecular Biotechnology, 2023
- Progress in building clinically relevant patient‐derived tumor xenograft models for cancer researchAnimal Models and Experimental Medicine, 2023
- Structural analysis of peptide binding to integrins for cancer detection and treatmentBiophysical Reviews, 2023
- Fibronectin type III domain-containing protein 5 promotes autophagy via the AMPK/mTOR signaling pathway in hepatocellular carcinoma cells, contributing to nab-paclitaxel chemoresistanceMedical Oncology, 2022
- Irisin/FNDC5 inhibits the epithelial–mesenchymal transition of epithelial ovarian cancer cells via the PI3K/Akt pathwayArchives of Gynecology and Obstetrics, 2022
- Cancer of the cervix uteriInternational Journal of Gynecology & Obstetrics, 2018
- Cervical cancer: A global health crisisCancer, 2017
- Irisin suppresses the migration, proliferation, and invasion of lung cancer cells via inhibition of epithelial-to-mesenchymal transitionBiochemical and Biophysical Research Communications, 2017
- FNDC5 overexpression and irisin ameliorate glucose/lipid metabolic derangements and enhance lipolysis in obesityBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2015
- Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE‐MRI in a longitudinal in vivo studyInternational Journal of Cancer, 2010